<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01054430</url>
  </required_header>
  <id_info>
    <org_study_id>TA-012</org_study_id>
    <nct_id>NCT01054430</nct_id>
  </id_info>
  <brief_title>To Assess the Safety of Avanafil in Healthy and Hepatically Impaired Male Subjects.</brief_title>
  <acronym>avanafil</acronym>
  <official_title>A PHASE I, OPEN LABEL, NON-RANDOMIZED, SINGLE-DOSE, PARALLEL-COHORT, MATCHED-CONTROL STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF AVANAFIL (TA-1790) IN SUBJECTS WITH HEPATIC IMPAIRMENT AND IN HEALTHY CONTROL MALE SUBJECTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VIVUS, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VIVUS, Inc.</source>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the single dose pharmacokinetics of avanafil in&#xD;
      subjects with hepatic impairment and in healthy control subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Single Dose Pharmacokinetics of avanafil</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>single dose safety</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Normal</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects with normal hepatic function</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild Hepatic Dysfunction</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects with mild hepatic impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate hepatic dysfunction</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects with moderal hepatice impairment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>avanafil</intervention_name>
    <description>200 mg avanafil tablets QD</description>
    <arm_group_label>Mild Hepatic Dysfunction</arm_group_label>
    <arm_group_label>Moderate hepatic dysfunction</arm_group_label>
    <arm_group_label>Normal</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male subjects must be 21-75 years of age; inclusive. Healthy control subjects (Cohort&#xD;
             1) must be medically healthy with clinically insignificant screening results and&#xD;
             hepatically impaired subjects (Cohorts 2 and 3) must have mild or moderate hepatic&#xD;
             impairment based on the Child-Pugh Classification.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Main exclusion criteria for healthy control subjects (Cohort 1) include history or&#xD;
             clinical evidence of clinically relevant cardiovascular (including thromboembolic&#xD;
             disorders), hepatic, renal, hematologic, endocrine, pulmonary, gastrointestinal,&#xD;
             psychiatric or neurological impairment; any clinically significant laboratory&#xD;
             abnormalities as judged by the investigatorInvestigator; systolic blood pressure &lt; 90&#xD;
             or &gt;160 mmHg; diastolic blood pressure &lt; 50 or &gt; 90 mmHg; allergy to or previous&#xD;
             adverse events with PDE5 inhibitors; use of prescription or over-the-counter drugs&#xD;
             that are known to interfere with metabolism by the cytochrome P450 3A4 enzyme within&#xD;
             30 days of screening; use of any investigational drug within 30 days of screening; use&#xD;
             of any prescription or over-the-counter drugs or herbal remedies within 14 days of&#xD;
             screening; history of alcohol or drug abuse within 18 months, history of smoking&#xD;
             within 6 months; positive breath alcohol test; positive serology for HIV, HCV, HBsAg;&#xD;
             blood donation or significant blood loss within 56 days of dosing; plasma donation&#xD;
             within 7 days of dosing.&#xD;
&#xD;
        Main exclusion criteria for hepatically impaired subjects (Cohorts 2 and 3) include any&#xD;
        significant concurrent medical condition or history of significant medical conditions other&#xD;
        than hepatic impairment that may affect the interpretation of the data or which otherwise&#xD;
        contraindicates participation in this study; acute exacerbation of or unstable hepatic&#xD;
        disease, as indicated by worsening of clinical and/or laboratory signs of hepatic&#xD;
        impairment, within the 2 weeks preceding study drug administration; history of esophageal&#xD;
        variceal bleeding within past 6 months; history of bleeding or non-bleeding gastric&#xD;
        varices; history of spontaneous bacterial peritonitis within the past 3 months; history of&#xD;
        portosystemic surgical shunt; autoimmune liver disease; history of organ transplant;&#xD;
        Wilson's disease; diagnosis of cholestatic liver disease (e.g., primary biliary cirrhosis&#xD;
        or primary sclerosing cholangitis); history of recent symptomatic cryoglobulinemia;&#xD;
        alcoholic hepatitis, determined clinically or by histology; initiation of any new&#xD;
        prescription or over the counter medications within 14 days before study drug&#xD;
        administration and hemoglobin &lt; 9.0 g/dL, positive for AFP.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shiyin Yee, PhD</last_name>
    <role>Study Director</role>
    <affiliation>VIVUS, Inc.</affiliation>
  </overall_official>
  <verification_date>January 2011</verification_date>
  <study_first_submitted>January 20, 2010</study_first_submitted>
  <study_first_submitted_qc>January 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2010</study_first_posted>
  <last_update_submitted>January 5, 2011</last_update_submitted>
  <last_update_submitted_qc>January 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>Wesley Day, VP Clinical</name_title>
    <organization>Vivus, Inc.</organization>
  </responsible_party>
  <keyword>Avanafil</keyword>
  <keyword>Hepatic</keyword>
  <keyword>Erectile Dysfunction</keyword>
  <keyword>Impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

